SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study

Inclusion Criteria

• •Male and female aged between 20 and 85 years.
• •Patients fulfilling one of the following diagnosis:
• •Five patients with chronic inflammatory demyelinating polyneuropathy on both clinical and neurophysiological grounds.
• •Five patients with proven genetic diagnosis of CMT1a or CMT1b
• •Five patients with anti-MAG polyneuropathy.
• •Electrophysiological parameters worsening for the past 3 years
• •Available EMG record, performed during the past 6 months to assess variability of NCV parameters
• •Signed and dated written informed consent to participate in the study in accordance with local regulations
• •Likely to be able to participate in all scheduled evaluation and complete all required study procedures,
• •In the opinion of the investigator, the patient will be compliant and have a high probability of completing the study.
• •Both male and female subjects who are not either surgically sterile (tubal ligation/obstruction or removal of ovaries or uterus) or post-menopausal (no spontaneous menstrual periods for at least one year confirmed by a negative hormone panel) must commit to using TWO highly effective method of birth control for the duration of the study and for two months after the treatment termination.